Trevi Therapeutics (TRVI) Short term Debt (2021 - 2023)

Trevi Therapeutics has reported Short term Debt for 3 years, with the latest figure at $7.5 million in Q1 2023.

• For the quarter ending Q1 2023, Short term Debt rose 6.89% year-over-year to $7.5 million; the trailing twelve-month figure through Mar 2023 stood at $7.5 million (up 6.89% YoY), and the FY2022 full-year result was $7.0 million, up 20.01% from the prior year.
• Short term Debt for Q1 2023 stood at $7.5 million, up from $7.0 million in the prior quarter.
• The five-year high for Short term Debt was $7.5 million in Q1 2023, with the low at $583000.0 in Q1 2021.
• Average Short term Debt over 3 years is $5.4 million, with a median of $7.0 million recorded in 2022.
• Year-over-year, Short term Debt jumped 1100.69% in 2022 and gained 6.89% in 2023.
• Tracing TRVI's Short term Debt over 3 years: stood at $5.8 million in 2021, then grew by 20.01% to $7.0 million in 2022, then rose by 6.89% to $7.5 million in 2023.
• The last three Short term Debt figures came in at $7.5 million (Q1 2023), $7.0 million (Q4 2022), and $7.0 million (Q3 2022), per Business Quant data.

Peer Comparison